Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/19022840/ below:

Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design

Randomized Controlled Trial

Affiliations

• ¹ Finnish Cancer Registry, Pieni Roobertinkatu 9, 00130 Helsinki, Finland. nea.malila@cancer.fi

• PMID: 19022840
• PMCID: PMC2593450
• DOI: 10.1136/bmj.a2261

Item in Clipboard

Randomized Controlled Trial

Nea Malila et al. BMJ. 2008.

• ¹ Finnish Cancer Registry, Pieni Roobertinkatu 9, 00130 Helsinki, Finland. nea.malila@cancer.fi

• PMID: 19022840
• PMCID: PMC2593450
• DOI: 10.1136/bmj.a2261

Item in Clipboard

Objectives: To report the sensitivities of the faecal occult blood test, screening episode, and screening programme for colorectal cancer and the benefits of applying a randomised design at the implementation phase of a new public health policy.

Design: Experimental design incorporated in public health evaluation using randomisation at individual level in the target population.

Setting: 161 of the 431 Finnish municipalities in 2004-6.

Participants: 106 000 adults randomised to screening or control arms. In total, 52 998 adults aged 60-64 in the screening arm received faecal occult blood test kits.

Main outcome measures: Test, episode, and programme sensitivities estimated by the incidence method and corrected for selective attendance and overdiagnosis.

Results: The response for screening was high overall (70.8%), and significantly better in women (78.1%) than in men (63.3%). The incidence of cancer in the controls was somewhat higher in men than in women (103 v 93 per 100 000 person years), which was not true for interval cancers (42 v 49 per 100 000 person years). The sensitivity of the faecal occult blood test was 54.6%. Only a few interval cancers were detected among those with positive test results, hence the episode sensitivity of 51.3% was close to the test sensitivity. At the population level the sensitivity of the programme was 37.5%.

Conclusions: Although relatively low, the sensitivity of screening for colorectal cancer with the faecal occult blood test in Finland was adequate. An experimental design is a prerequisite for evaluation of such a screening programme because the effectiveness of preventing deaths is likely to be small and results may otherwise remain inconclusive. Thus, screening for colorectal cancer using any primary test modality should be launched in a public health programme with randomisation of the target population at the implementation phase.

PubMed Disclaimer

Competing interests: None declared.

Flow chart of Finnish colorectal cancer screening…

Flow chart of Finnish colorectal cancer screening programme. Screen detected cancers provide no follow-up time…

Flow chart of Finnish colorectal cancer screening programme. Screen detected cancers provide no follow-up time in current analysis

• Screening for colorectal cancer.

  Austoker J, Hewitson P. Austoker J, et al. BMJ. 2008 Nov 20;337:a2207. doi: 10.1136/bmj.a2207. BMJ. 2008. PMID: 19022839 No abstract available.

• Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.

  Malila N, Oivanen T, Hakama M. Malila N, et al. Z Gastroenterol. 2008 Apr;46 Suppl 1:S25-8. doi: 10.1055/s-2007-963490. Z Gastroenterol. 2008. PMID: 18368636

• Colorectal cancer screening in Finland: details of the national screening programme implemented in Autumn 2004.

  Malila N, Anttila A, Hakama M. Malila N, et al. J Med Screen. 2005;12(1):28-32. doi: 10.1258/0969141053279095. J Med Screen. 2005. PMID: 15814016 Clinical Trial.

• Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.

  Blom J, Törnberg S. Blom J, et al. J Med Screen. 2017 Sep;24(3):146-152. doi: 10.1177/0969141316682983. Epub 2017 Jan 31. J Med Screen. 2017. PMID: 28142309

• Screening for colorectal cancer using the faecal occult blood test, Hemoccult.

  Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Hewitson P, et al. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD001216. doi: 10.1002/14651858.CD001216.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253456 Free PMC article. Review.

• Screening for colorectal cancer using the faecal occult blood test, hemoccult. Towler BP, Irwig L, Glasziou P, Weller D, Kewenter J. Towler BP, et al. Cochrane Database Syst Rev. 2000;(2):CD001216. doi: 10.1002/14651858.CD001216. Cochrane Database Syst Rev. 2000. PMID: 10796760 Updated. Review.

• Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: population-based registry study from Finland.

  Sarkeala T, Färkkilä M, Anttila A, Hyöty M, Kairaluoma M, Rautio T, Voutilainen M, Helander S, Jäntti M, Lehtinen M, Patrikka L, Malila N, Heinävaara S. Sarkeala T, et al. BMJ Open. 2021 Feb 8;11(2):e046667. doi: 10.1136/bmjopen-2020-046667. BMJ Open. 2021. PMID: 33558363 Free PMC article.

• A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel Cancer Screening Programme.

  Morris EJ, Whitehouse LE, Farrell T, Nickerson C, Thomas JD, Quirke P, Rutter MD, Rees C, Finan PJ, Wilkinson JR, Patnick J. Morris EJ, et al. Br J Cancer. 2012 Aug 21;107(5):757-64. doi: 10.1038/bjc.2012.331. Epub 2012 Jul 31. Br J Cancer. 2012. PMID: 22850549 Free PMC article.

• Urinary Volatile Organic Compound Testing in Fast-Track Patients with Suspected Colorectal Cancer.

  Boulind CE, Gould O, de Lacy Costello B, Allison J, White P, Ewings P, Wicaksono AN, Curtis NJ, Pullyblank A, Jayne D, Covington JA, Ratcliffe N, Turner C, Francis NK. Boulind CE, et al. Cancers (Basel). 2022 Apr 24;14(9):2127. doi: 10.3390/cancers14092127. Cancers (Basel). 2022. PMID: 35565258 Free PMC article.

• Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.

  Mlakar DN, Bric TK, Škrjanec AL, Krajc M. Mlakar DN, et al. Radiol Oncol. 2018 Jul 12;52(4):413-421. doi: 10.2478/raon-2018-0025. Radiol Oncol. 2018. PMID: 30511936 Free PMC article.

• Effectiveness of screening for colorectal cancer with a faecal occult-blood test, in Finland.

  Pitkäniemi J, Seppä K, Hakama M, Malminiemi O, Palva T, Vuoristo MS, Järvinen H, Paimela H, Pikkarainen P, Anttila A, Elovainio L, Hakulinen T, Karjalainen S, Pylkkänen L, Rautalahti M, Sarkeala T, Vertio H, Malila N. Pitkäniemi J, et al. BMJ Open Gastroenterol. 2015 Jun 8;2(1):e000034. doi: 10.1136/bmjgast-2015-000034. eCollection 2015. BMJ Open Gastroenterol. 2015. PMID: 26462283 Free PMC article.

1. 1. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71. - PubMed
2. 1. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer control study. N Engl J Med 1993;328:1365-71. - PubMed
3. 1. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7. - PubMed
4. 1. Kewenter J, Brevinge H, Engaras B, Haglind E, Ahren C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol 1994;29:468-73. - PubMed
5. 1. Malila N, Anttila A, Hakama M. Colorectal cancer screening in Finland: details of the national screening programme implemented in Autumn 2004. J Med Screen 2005;12:28-32. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3